Skip to content
Search

Latest Stories

Reckitt Benckiser buys US infant and child nutrition specialist Mead Johnson

British consumer health giant Reckitt Benckiser on Friday (10) bought US infant and child nutrition specialist Mead Johnson for $16.6 billion (£13.29 billion) in a takeover which targets rapid expansion in Asia.

The friendly deal was pitched at $90 (£72) per share and will “significantly strengthen” its presence in developing markets like China, Reckitt said in a statement.


The transaction will also take Reckitt, whose brands include Durex condoms and Nurofen painkillers, into the baby-food market for the first time.

The deal, which values Illinois-based Mead Johnson at $17.9 billion (£14.34 billion) including debt, is expected to generate £200 million of annual cost savings within three years of completion.

“The acquisition of Mead Johnson is a significant step forward in Reckitt Benckiser’s journey as a leader in consumer health,” said chief executive Rakesh Kapoor.

He described Mead Johnson’s “Enfa” baby food brands as “a natural extension” to Reckitt Benckiser’s consumer health portfolio.

Under Kapoor’s leadership, Reckitt has been on the lookout for a major acquisition for some time, and the Mead takeover will boost its US and Asia business and expand its health division.

The transaction would strengthen the British group’s position in developing markets - which will account for approximately 40 per cent of the combined group’s sales.

Mead Johnson chairman James Cornelius said the deal would provide “tremendous value” and described Reckitt Benckiser “with its strong financial base, broad global footprint, consumer branding expertise and dynamic business model (as) an ideal partner.”

Mead Johnson sells 70 products in over 50 countries, including its flagship “Enfa” line.

The US company, which booked a net profit of $545 million (£436 million) in 2016 on sales of $3.7 billion (£3 billion), generates nearly half its revenues in Asia.

Mead Johnson belonged to Bristol-Myers Squibb until 2009, when its shares were floated on the stock exchange. It has regularly been the focus of takeover speculation, with food giants Danone and Nestle previously tipped as potential buyers.

London-listed Reckitt Benckiser, which generated sales of £8.87 billion in 2015, twice downgraded its forecast for organic, or self-generated, sales growth during last year.

Its diverse portfolio of brands also includes Air Wick air fresheners, Dettol surface cleaners, Finish dishwasher tablets and Strepsils throat lozenges.

In early morning London trade, Reckitt’s share price rose 0.75 per cent to 7,293 pence on the British capital’s benchmark FTSE 100 index, which gained 0.54 per cent to 7,268.40 points.

The company made the announcement alongside its full-year results. Net profit, or earnings after taxation, rose five percent to £1.83 billion in 2016 on a 2.0-percent increase in revenues to £9.89 billion.

“2016 was a good year in which we achieved broad-based growth and excellent margin expansion, despite challenging markets and an unusual number of issues,” Kapoor added.

“In 2017, we expect macro conditions to remain challenging, and for a number of existing headwinds to persist in the first half.”

More For You

modi-trump-getty
Trump shakes hands with Modi during a joint press conference at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)

Key issues in India, US trade talks

TRADE talks between India and the US have hit a roadblock over disagreements on duties for auto components, steel and farm goods, Indian government sources said to Reuters, dashing hopes of reaching an interim deal ahead of president Donald Trump's July 9 deadline to impose reciprocal tariffs.

Here are the key issues at play:

Keep ReadingShow less
Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less